3.25

4.13% -0.14

After Hours: 3.28 0.03 +0.92%

X 4 Pharmaceuticals Inc (XFOR)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

X 4 Pharmaceuticals Inc stock is traded at $3.25, with a volume of 138.18K. It is down -4.13% in the last 24 hours and down -39.08% over the past month. X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare diseases of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

Previous Close:

$3.39

Open:

$3.37

24h Volume:

138.18K

Relative Volume:

1.29

Market Cap:

$18.82M

Revenue:

Net Income/Loss:

$-16.76M

P/E Ratio:

-40.62

EPS:

-0.08

Net Cash Flow:

$-132.97M

1W Performance:

+17.33%

1M Performance:

-39.08%

6M Performance:

-72.18%

1Y Performance:

-88.51%

1-Day Range:

$3.16

$3.49

1-Week Range:

$2.7028

$3.53

52-Week Range:

$2.67

$33.90

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

Name

X 4 Pharmaceuticals Inc

Sector

Healthcare (1173)

Industry

Biotechnology (672)

Phone

857-529-8300

Address

61 NORTH BEACON STREET, BOSTON, MA

Employee

143

Twitter

@x4pharma

Next Earnings Date

2025-03-25

Latest SEC Filings

XFOR's Discussions on Twitter

Compare XFOR with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
XFOR X 4 Pharmaceuticals Inc	3.25	15.69M	0	-16.76M	-132.97M	-0.08
ONC Beigene Ltd Adr	240.41	25.61B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	445.10	114.83B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.30	41.82M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	591.85	66.38B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	73.93	6.36B	0	-153.72M	-103.81M	-2.00

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-12-23	Downgrade	B. Riley Securities	Buy → Neutral
Aug-30-23	Resumed	B. Riley Securities	Buy
Dec-22-22	Initiated	Cantor Fitzgerald	Overweight
Dec-12-22	Initiated	Piper Sandler	Overweight
Dec-23-19	Initiated	Oppenheimer	Outperform
Dec-18-19	Initiated	ROTH Capital	Buy
Dec-09-19	Upgrade	Citigroup	Neutral → Buy
Dec-05-19	Initiated	B. Riley FBR	Buy
Jun-07-19	Initiated	Stifel	Buy
Jun-05-19	Initiated	Cowen	Outperform

View All

X 4 Pharmaceuticals Inc Stock (XFOR) Latest News

May 27, 2025

SEC Form DEFA14A filed by Vanda Pharmaceuticals Inc. - Quantisnow

May 27, 2025

May 22, 2025

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Twinbeech Capital LP - MarketBeat

May 22, 2025

Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace

May 22, 2025

May 21, 2025

President and CEO Polymeropoulos Mihael Hristos bought $43,995 worth of shares (10,000 units at $4.40), increasing direct ownership by 0.43% to 2,325,731 units (SEC Form 4) - Quantisnow

May 21, 2025

May 19, 2025

President and CEO Polymeropoulos Mihael Hristos bought $84,472 worth of shares (20,000 units at $4.22), increasing direct ownership by 0.87% to 2,315,731 units (SEC Form 4) - Quantisnow

May 19, 2025

23andMe to Be Bought by Regeneron Pharmaceuticals, a Biotech Company, for $256 Million - The New York Times

May 19, 2025

Bankrupt 23andMe Expected to Be Purchased for $256M - People.com

May 19, 2025

May 16, 2025

Vanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025 - Quantisnow

May 16, 2025

May 14, 2025

X4 Pharmaceuticals Announces Upcoming Presentation Of Phase 2 Chronic Neutropenia Trial Data At The 30Th Annual Eha Congress - marketscreener.com

May 14, 2025

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data at the 30th Annual EHA Congress - marketscreener.com

May 14, 2025

X4 Pharmaceuticals Announces Upcoming Presentation of Phase 2 Chronic Neutropenia Trial Data At the 30Th Annual Eha Congress - marketscreener.com

May 14, 2025

May 13, 2025

Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... - Yahoo Finance

May 13, 2025

May 08, 2025

Fierce Biotech Layoff Tracker 2025: Insitro shrinks team by 22%; Shape ships out staff - Fierce Biotech

May 08, 2025

May 07, 2025

Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail

May 07, 2025

May 04, 2025

HC Wainwright Raises X4 Pharmaceuticals (NASDAQ:XFOR) Price Target to $7.00 - Defense World

May 04, 2025

May 02, 2025

Director Hayden Michael R bought $477,900 worth of shares (15,000 units at $31.86), increasing direct ownership by 43% to 50,219 units (SEC Form 4) - Quantisnow

May 02, 2025

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - TradingView

May 02, 2025

X4 Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 02, 2025

XFOR: HC Wainwright Raises Price Target for X4 Pharmaceuticals | - GuruFocus

May 02, 2025

Vanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025 - Quantisnow

May 02, 2025

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 02, 2025